The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel
Fatima N, Meola A, Ding VY, Pollom E, Soltys SG, Chuang CF, Shahsavari N, Hancock SL, Gibbs IC, Adler JR, Chang SD.J | Neurosurg | 2021
The volumetric response of brain metastases after stereotactic radiosurgery and its post-treatment implications
Sharpton SR, Oermann EK, Moore DT, Schreiber E, Hoffman R, Morris DE, Ewend MG | Neurosurgery | 2014
Efficacy, safety and outcome of frameless image-guided robotic radiosurgery for brain metastases after whole brain radiotherapy
Lohkamp LN, Vajkoczy P, Budach V, Kufeld M | J Neurooncol | 2018
Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases
Martinage G, Geffrelot J, Stefan D, Bogart E, Rault E, Reyns N, Emery E, Makhloufi-Martinage S, Mouttet-Audouard R, Basson L, Mirabel X, Lartigau E, Pasquier D | Front Oncol | 2019
A Second Course of Stereotactic Image-Guided Robotic Radiosurgery for Patients with Cerebral Metastasis
Jiang X, Wang H, Song Y, Wang X, Li F, Dong Y, Wang J, Chen H, Yuan Z | World Neurosurg | 2019
A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases
El Shafie RA, Celik A, Weber D, Schmitt D, Lang K, König L, Bernhardt D, Höne S, Forster T, von Nettelbladt B, Adeberg S, Debus J, Rieken S | J Neurooncol | 2020
Clinical outcome after CyberKnife® radiosurgery re-irradiation for recurrent brain metastases
Berber T, Raturi V, Aksaray F, Hojo H, Fujisawa T, Ohyoshi H | Cancer Radiother | 2021
Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
Borzillo V, Di Franco R, Giannarelli D, Cammarota F, Scipilliti E, D’Ippolito E, Petito A, Serra M, Falivene S, Grimaldi AM, Simeone E, Festino L, Vanella V, Trojaniello C, Vitale MG, Madonna G, Ascierto PA, Muto P | Cancers (Basel) | 2021
Treatment of Chordomas and Chondrosarcomas With CyberKnife Robotic Hypofractionated Radiosurgery: A Single Institution Experience
Sallabanda M, Garcia R, Lorenzana L, Santaolalla I, Abarca J, Sallabanda K | Cureus | 2021
Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection
Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, Staddon A, Hartner L, Hahn SM, Glatstein E, Simone CB | J Surg Oncol. | 2016
Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL | Front Oncol | 2015
Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)
Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015
Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review
Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016
Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer
Morgenthaler J, Köhler C, Budach V, Sehouli J, Stromberger C, Besserer A, Trommer M, Baues C, Marnitz S | Strahlenther Onkol | 2021
CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van […]
Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
Fuller DB, Naitoh J, Shirazi R, Crabtree T, Mardirossian G | Front Oncol | 2020
